Core Concepts
Secukinumab and adalimumab-adaz show similar efficacy in limiting spinal radiographic progression in axial spondyloarthritis.
Abstract
The content discusses a phase 3b, randomized controlled trial comparing the efficacy of secukinumab and adalimumab-adaz in limiting spinal radiographic progression in patients with radiographic axial spondyloarthritis (r-axSpA). Key highlights include:
- Both drugs target different pathways but show similar efficacy.
- Limited data exist on the effect of biologic disease-modifying antirheumatic drugs (bDMARDs) in slowing radiographic progression in axSpA.
- The SURPASS trial enrolled 859 biologic-naive adult patients with r-axSpA.
- No significant differences were observed between the treatment groups in terms of radiographic progression.
- Both secukinumab and adalimumab-adaz demonstrated effectiveness in improving symptoms and physical function.
- The study did not definitively answer whether bDMARDs can modify structural progression.
- Researchers continue to explore mechanisms of disease progression in axSpA.
Stats
The proportion of patients with no radiographic progression at week 104 was 66.1% in the secukinumab 150-mg arm, 66.9% in the secukinumab 300 mg arm, and 65.6% in the adalimumab-adaz arm.
The mean change from baseline in modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was 0.54, 0.55, and 0.72, respectively.
More than half of the patients with at least one syndesmophyte at baseline did not develop new syndesmophytes over the 2-year period.
Quotes
"Anti-TNF therapy has been considered the gold standard treatment for axial spondyloarthritis in terms of slowing or halting radiographic progression." - Dr. Xenofon Baraliakos
"After 2 years, no difference was observed in the percentage of patients with no progression across the study arms." - Dr. Alexandre Sepriano